TRPV1 and Schnyder corneal dystrophy: Much of the biological data are limited to murine models, but because of the availability of an FDA‐approved direct agonistic inhibitor of TRPV1, high‐dose (8%) topical capsaicin (Qutenza, Averitas Pharma), that receptor is well suited as a starting point for the back‐translation of these mechanisms into human models of SCD pain.